| pubmed-article:1161995 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1161995 | lifeskim:mentions | umls-concept:C0009170 | lld:lifeskim |
| pubmed-article:1161995 | lifeskim:mentions | umls-concept:C0025810 | lld:lifeskim |
| pubmed-article:1161995 | lifeskim:mentions | umls-concept:C0036516 | lld:lifeskim |
| pubmed-article:1161995 | lifeskim:mentions | umls-concept:C0597198 | lld:lifeskim |
| pubmed-article:1161995 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:1161995 | lifeskim:mentions | umls-concept:C1314677 | lld:lifeskim |
| pubmed-article:1161995 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:1161995 | pubmed:dateCreated | 1975-12-4 | lld:pubmed |
| pubmed-article:1161995 | pubmed:abstractText | Cocaine, methylphenidate and secobarbital were compared on a drug maintained progressive-ratio procedure in baboon subjects. Trials, scheduled throughout the day, occurred at a minimum interval of 3 hrs after completion of the preceding trial. A ratio response requirement on the "initiate" lever was required during each trial which terminated in a single intravenous infusion of drug. A drug was introduced on the progressive-ratio procedure with a low ratio requirement in order to obtain a baseline performance of a high stable frequency of trial completion. The ratio requirement was systematically increased every 7 days until the "breaking point" when the rate of completing trials fell below a criterion level. Within-subject comparison revealed that cocaine produced higher breaking points than methylphenidate at the same absolute dose, 0.4 mg/kg. At the range of doses studied, manipulation of doses of methylphenidate (0.1-0.8 mg/kg) and cocaine (0.4-1.6 mg/kg) had little effect on breaking point. In contrast, increasing doses of secobarbital (6.0 and 12.0 mg/kg) produce higher breaking points within the same subjects. | lld:pubmed |
| pubmed-article:1161995 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1161995 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1161995 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1161995 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1161995 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1161995 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1161995 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1161995 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:1161995 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:1161995 | pubmed:author | pubmed-author:BradyJ VJV | lld:pubmed |
| pubmed-article:1161995 | pubmed:author | pubmed-author:GriffithsR... | lld:pubmed |
| pubmed-article:1161995 | pubmed:author | pubmed-author:FindleyJ DJD | lld:pubmed |
| pubmed-article:1161995 | pubmed:author | pubmed-author:RobinsonW WWW | lld:pubmed |
| pubmed-article:1161995 | pubmed:author | pubmed-author:Dolan-Gutcher... | lld:pubmed |
| pubmed-article:1161995 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1161995 | pubmed:day | 23 | lld:pubmed |
| pubmed-article:1161995 | pubmed:volume | 43 | lld:pubmed |
| pubmed-article:1161995 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1161995 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1161995 | pubmed:pagination | 81-3 | lld:pubmed |
| pubmed-article:1161995 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:meshHeading | pubmed-meshheading:1161995-... | lld:pubmed |
| pubmed-article:1161995 | pubmed:year | 1975 | lld:pubmed |
| pubmed-article:1161995 | pubmed:articleTitle | Comparison of progressive-ratio performance maintained by cocaine, methylphenidate and secobarbital. | lld:pubmed |
| pubmed-article:1161995 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1161995 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1161995 | pubmed:publicationType | Research Support, U.S. Gov't, Non-P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1161995 | lld:pubmed |
